Mathias Vormehr

Company: BioNTech AG

Seminars:

Panel Discussion: Exploring the Bestin- Class Adjuvant to Improve Patient Response to Neoantigen Therapy 3:00 pm

Discussing the best approach to turn the ‘cold tumor’ into a ‘hot tumor’. Outlining the variety of neoadjuvant methods to prime immune responses to neoantigen vaccination Exploring the potential of a mRNA adjuvant if an mRNA vaccine platform is used for neoantigen deliveryRead more

day: Day Three Track A AM

Overcoming Challenges for Effective Cancer Vaccine Therapy 2:30 pm

Improving vaccine activity by combining with RNA encoded cytokines Novel treatments to overcome immune escape via MHC I lossRead more

day: Day Three Track A AM